Welcome to our dedicated page for Ion Acquisition 3 news (Ticker: IACC), a resource for investors and traders seeking the latest updates and insights on Ion Acquisition 3 stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ion Acquisition 3's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ion Acquisition 3's position in the market.
ION Acquisition Corp 3 Ltd. announced the completion of its initial public offering, raising $253 million by selling 25.3 million Class A ordinary shares at $10.00 each, including 3.3 million shares from the underwriters' over-allotment. The shares began trading on the NYSE under the ticker symbol IACC on April 30, 2021. The Company aims to pursue business combinations with rapidly growing Israeli tech companies. The offering was managed by Morgan Stanley and Goldman Sachs, with a registration statement effective on April 29, 2021.
FAQ
What is the market cap of Ion Acquisition 3 (IACC)?
